ARF-BP1 as a potential therapeutic target.

Chen D; Brooks CL; Gu W

首页> 外文期刊>The British journal of cancer >ARF-BP1 as a potential therapeutic target.

【24h】

ARF-BP1 as a potential therapeutic target.

机译：ARF-BP1作为一个潜在的治疗目标。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

In this review, we discuss the recent identification of ARF-BP1 (also known as Mule, UREB1, E3(histone), LASU1, and HectH9). ARF-BP1, a HECT domain-containing E3 ubiquitin ligase, interacts with ARF and p53. Its ubiquitin ligase activity is inhibited by ARF. Inactivation of ARF-BP1 stabilised p53 and induced apoptosis. Notably, inactivation of ARF-BP1 also caused cell growth repression in p53-null cells and breast cancer cells with mutant p53. Thus, ARF-BP1 emerges as a novel therapeutic target against cancer regardless of p53 status.

机译：在本文中,我们讨论最近的识别ARF-BP1(也称为骡子,一个HECT domain-containing E3泛素连接酶,与东盟地区论坛和p53。通过论坛活动抑制。ARF-BP1稳定p53和诱导细胞凋亡。值得注意的是,ARF-BP1也引起细胞失活增长压制p53-null细胞和乳房癌细胞对p53基因突变。成为一种新颖的治疗目标癌症不管p53的地位。

著录项

来源
《The British journal of cancer》 |2006年第11期|1555-1558|共4页
作者
Chen D; Brooks CL; Gu W;
展开▼
作者单位

Institute for Cancer Genetics, Department of Pathology, College of Physicians and Surgeons, Columbia University, 1150 St Nicholas Ave, New York, NY 10032, USA.;

ol.net;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类肿瘤学;
关键词
Neoplasms; Tumor Suppressor Protein p53; Cancerubiquitin protein ligase;

机译：肿瘤;肿瘤抑制蛋白p53;Cancerubiquitin蛋白连接酶;

相似文献

外文文献
中文文献
专利

1. Exclusive Option to License and Develop mGluR4 PAMs for Parkinson's Disease Granted Domain Therapeutics SA announced today that Domain Therapeutics grants Prexton [J] . Lab Asia group Lab Asia . 2013,第1期

机译：为帕金森氏病提供许可和开发MGLUR4 PAMS的独家选项，授予了域Therapeutics SA今天宣布域Therapeutics授予Prexton
2. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15 [J] . InoueS., HaoZ., EliaA.J., Genes and Development: a Journal Devoted to the Molecular Analysis of Gene Expression in Eukaryotes, Prokaryotes, and Viruses . 2013,第10期

机译：Mule / Huwe1 / Arf-BP1通过阻止c-Myc / Miz1介导的p21和p15下调来抑制Ras驱动的肿瘤发生
3. Homeostatic defects in B cells deficient in the E3 ubiquitin ligase ARF-BP1 are restored by enhanced expression of MYC [J] . QiC.-F., ZhangR., SunJ., Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis . 2013,第12期

机译：缺乏E3泛素连接酶ARF-BP1的B细胞的体内稳态缺陷可通过增强MYC表达来恢复
4. DEB YE POTENTIALS FOR HETEROGENEOUS MEDIA [C] . N.S. Panamarev, V.A. Donchenko, Al.A. Zemlyanov, International symposium on atmospheric and ocean optics: atmospheric physics . 2017

机译：D E bye potentials for heterogeneous Media
5. Developing Heterostructured Nanoparticles for Cancer Therapeutics =納米異質結構在癌症治療中的應用 [D] . Yang, Jingnan. 2019

机译：Developing Heterostructured Nanoparticles for Cancer Therapeutics =纳米异质结构在癌症治疗中的应用
6. Radon potential geologic formations and lung cancer risk [O] . Ellen J. Hahn, Yevgeniya Gokun, William M. Andrews Jr., 2015

机译：potential势地质形成和肺癌风险
7. Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2? [O] . Andrew V. Stachulski, Joshua Taujanskas, Sophie L. Pate, 2020

机译：Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
8. Axerion Therapeutics Generally Claimed Allowable Recovery Act Grant Costs. [R] . 2012

机译：axerion Therapeutics一般声称允许恢复法案授予费用。

ARF-BP1 as a potential therapeutic target.

摘要

著录项

相似文献

相关主题

期刊订阅